CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer

(2017) E Zoni et al.   ONCOGENE

Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma

(2016) Jordi Bruix et al.   GASTROENTEROLOGY

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

(2016) Linda S. Steelman et al.   Aging-US

Inhibition of TGFβ type I receptor activity facilitates liver regeneration upon acute CCl4 intoxication in mice

(2015) Sofia Karkampouna et al.   ARCHIVES OF TOXICOLOGY

miR-25 Modulates Invasiveness and Dissemination of Human Prostate Cancer Cells via Regulation of αv- and α6-Integrin Expression

(2015) E. Zoni et al.   CANCER RESEARCH

Cripto-1 as a novel therapeutic target for triple negative breast cancer

(2015) Nadia P. Castro et al.   Oncotarget

CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities

(2015) Stéphane Terry et al.   Oncotarget

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2015) et al.   JOURNAL OF HEPATOLOGY

Cripto haploinsufficiency affects in vivo colon tumor development

(2014) EMILIA GIORGIO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance

(2014) Kang-Seo Park et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma

(2014) B. Zhai et al.   MOLECULAR CANCER THERAPEUTICS

The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition

(2014) Malgorzata Klauzinska et al.   SEMINARS IN CANCER BIOLOGY

Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer

(2014) Chun-Hua Xu et al.   TUMOR BIOLOGY

CRIPTO/GRP78 Signaling Maintains Fetal and Adult Mammary Stem Cells Ex Vivo

(2014) Benjamin T. Spike et al.   Stem Cell Reports

The significance of a Cripto-1-positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics

(2013) Luigi Strizzi et al.   CELL CYCLE

NANOG promotes liver cancer cell invasion by inducing epithelial–mesenchymal transition through NODAL/SMAD3 signaling pathway

(2013) Chun Sun et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration

(2013) Meritxell Huch et al.   NATURE

GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN

(2013) W-T Chen et al.   ONCOGENE

Role of Cripto-1 during Epithelial-to-Mesenchymal Transition in Development and Cancer

(2012) Maria C. Rangel et al.   AMERICAN JOURNAL OF PATHOLOGY

Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis

(2012) Peter C. Gray et al.   FEBS LETTERS

Global cancer transitions according to the Human Development Index (2008–2030): a population-based study

(2012) Freddie Bray et al.   LANCET ONCOLOGY

A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways

(2011) Ting-Chun Kuo et al.   BIOCHEMICAL PHARMACOLOGY

Systemic Therapy in Hepatocellular Carcinoma

(2011) Stephen H. Wrzesinski et al.   Clinics in Liver Disease

Regulation of extra-embryonic endoderm stem cell differentiation by Nodal and Cripto signaling

(2011) M. K.-d. Julio et al.   DEVELOPMENT

Liver-specific loss of glucose-regulated protein 78 perturbs the unfolded protein response and exacerbates a spectrum of liver diseases in mice

(2011) Cheng Ji et al.   HEPATOLOGY

Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells

(2011) K.-F. Chen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma Patients

(2010) S. Roessler et al.   CANCER RESEARCH

Cripto-1: an embryonic gene that promotes tumorigenesis

(2010) Nadia Pereira de Castro et al.   Future Oncology

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma

(2010) Ghassan K. Abou-Alfa et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Profiling Cancer Stem Cells in Androgen-Responsive and Refractory Human Prostate Tumor Cell Lines

(2009) Letizia Cocciadiferro et al.   Annals of the New York Academy of Sciences

Unknown

(2009) Valeria Mas et al.   MOLECULAR MEDICINE

Development of a novel mouse glioma model using lentiviral vectors

(2009) Tomotoshi Marumoto et al.   NATURE MEDICINE

Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways

(2009) J A Kelber et al.   ONCOGENE

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE